ArticleAnnals of medicine2025
The clinicopathologic characteristics and tumor immune microenvironment of pulmonary enteric adenocarcinoma.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary enteric adenocarcinoma (PEAC) as a rare subtype of lung adenocarcinoma is sparsely reported. Currently, to achieve effective treatment and accurate prognosis prediction, the exploration of molecular markers is ongoing.
methodsThis study retrospectively enrolled 10 patients with PEAC confirmed by pathology at Zhejiang Cancer Hospital from April 2015 to July 2021. The investigation focused on their clinicopathological features and the tumor immune microenvironment. The expression of LAG-3, PD-L1, and MMR proteins was determined by immunohistochemistry in 7 patients with adequate tissue. Simultaneously, the levels and distribution of CD3, CD8A, CD45RO and PanCK in PEAC patients were measured by multiple immunohistochemical methods to explore and analyze the classification of TIME.
resultsA total of 10 patient pathologically diagnosed as PEAC, the mean age at diagnosis is 60.3 years, and 60% of them were male. The median follow-up for PFS subjects was 16.7 months (95%CI: 4.92-28.48 months). The median OS was 93.9 months (95% CI: 0-216.03 months). All the 7 patients in this study exhibited microsatellite stability (MSS), and PD-L1 expression was negative. Of the 7 patients, only one expressed LAG-3. The analysis of TIME in PEAC patients suggested 'cold tumors', meaning these patients may not benefit from immunotherapy.
conclusionPEAC is a rare histological variant of LAUD that occurs predominantly in middle-aged and elderly males. Its morphological characteristics are similar to colorectal adenocarcinoma, and the NaspinA, TTF-1, CK7, CDX2 and CK20 are beneficial for diagnosis. In this study, PEAC patients showed low CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.